Amar U Kishan1, Ryan R Cook2, Jay P Ciezki3, Ashley E Ross4, Mark M Pomerantz5, Paul L Nguyen6, Talha Shaikh7, Phuoc T Tran8, Kiri A Sandler1, Richard G Stock9, Gregory S Merrick10, D Jeffrey Demanes1, Daniel E Spratt11, Eyad I Abu-Isa11, Trude B Wedde12, Wolfgang Lilleby12, Daniel J Krauss13, Grace K Shaw5, Ridwan Alam4, Chandana A Reddy3, Andrew J Stephenson14, Eric A Klein14, Daniel Y Song8, Jeffrey J Tosoian4, John V Hegde1, Sun Mi Yoo1, Ryan Fiano10, Anthony V D'Amico6, Nicholas G Nickols1,15, William J Aronson16, Ahmad Sadeghi15, Stephen Greco8, Curtiland Deville8, Todd McNutt8, Theodore L DeWeese8, Robert E Reiter16, Johnathan W Said17, Michael L Steinberg1, Eric M Horwitz7, Patrick A Kupelian1,18, Christopher R King1. 1. Department of Radiation Oncology, University of California, Los Angeles. 2. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles. 3. Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio. 4. Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 6. Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 7. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 8. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 9. Department of Radiation Oncology, The Icahn School of Medicine at Mount Sinai, New York, New York. 10. Schiffler Cancer Center, Wheeling Hospital, Wheeling Jesuit University, Wheeling, West Virginia. 11. Department of Radiation Oncology, University of Michigan, Ann Arbor. 12. Department of Oncology, Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway. 13. Oakland University William Beaumont School of Medicine, Royal Oak, Michigan. 14. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. 15. Department of Radiation Oncology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, California. 16. Department of Urology, University of California, Los Angeles. 17. Department of Pathology, University of California, Los Angeles. 18. Varian Medical Systems, Palo Alto, California.
Abstract
Importance: The optimal treatment for Gleason score 9-10 prostate cancer is unknown. Objective: To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Design, Setting, and Participants: Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated between 2000 and 2013. Exposures: Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy. Main Outcomes and Measures: The primary outcome was prostate cancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes. Results: Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years, 91 RP, 186 EBRT, and 90 EBRT+BT patients had died. Adjusted 5-year prostate cancer-specific mortality rates were RP, 12% (95% CI, 8%-17%); EBRT, 13% (95% CI, 8%-19%); and EBRT+BT, 3% (95% CI, 1%-5%). EBRT+BT was associated with significantly lower prostate cancer-specific mortality than either RP or EBRT (cause-specific HRs of 0.38 [95% CI, 0.21-0.68] and 0.41 [95% CI, 0.24-0.71]). Adjusted 5-year incidence rates of distant metastasis were RP, 24% (95% CI, 19%-30%); EBRT, 24% (95% CI, 20%-28%); and EBRT+BT, 8% (95% CI, 5%-11%). EBRT+BT was associated with a significantly lower rate of distant metastasis (propensity-score-adjusted cause-specific HRs of 0.27 [95% CI, 0.17-0.43] for RP and 0.30 [95% CI, 0.19-0.47] for EBRT). Adjusted 7.5-year all-cause mortality rates were RP, 17% (95% CI, 11%-23%); EBRT, 18% (95% CI, 14%-24%); and EBRT+BT, 10% (95% CI, 7%-13%). Within the first 7.5 years of follow-up, EBRT+BT was associated with significantly lower all-cause mortality (cause-specific HRs of 0.66 [95% CI, 0.46-0.96] for RP and 0.61 [95% CI, 0.45-0.84] for EBRT). After the first 7.5 years, the corresponding HRs were 1.16 (95% CI, 0.70-1.92) and 0.87 (95% CI, 0.57-1.32). No significant differences in prostate cancer-specific mortality, distant metastasis, or all-cause mortality (≤7.5 and >7.5 years) were found between men treated with EBRT or RP (cause-specific HRs of 0.92 [95% CI, 0.67-1.26], 0.90 [95% CI, 0.70-1.14], 1.07 [95% CI, 0.80-1.44], and 1.34 [95% CI, 0.85-2.11]). Conclusions and Relevance: Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer-specific mortality and longer time to distant metastasis compared with EBRT with androgen deprivation therapy or with RP.
Importance: The optimal treatment for Gleason score 9-10 prostate cancer is unknown. Objective: To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Design, Setting, and Participants: Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated between 2000 and 2013. Exposures: Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy. Main Outcomes and Measures: The primary outcome was prostate cancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes. Results: Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years, 91 RP, 186 EBRT, and 90 EBRT+BT patients had died. Adjusted 5-year prostate cancer-specific mortality rates were RP, 12% (95% CI, 8%-17%); EBRT, 13% (95% CI, 8%-19%); and EBRT+BT, 3% (95% CI, 1%-5%). EBRT+BT was associated with significantly lower prostate cancer-specific mortality than either RP or EBRT (cause-specific HRs of 0.38 [95% CI, 0.21-0.68] and 0.41 [95% CI, 0.24-0.71]). Adjusted 5-year incidence rates of distant metastasis were RP, 24% (95% CI, 19%-30%); EBRT, 24% (95% CI, 20%-28%); and EBRT+BT, 8% (95% CI, 5%-11%). EBRT+BT was associated with a significantly lower rate of distant metastasis (propensity-score-adjusted cause-specific HRs of 0.27 [95% CI, 0.17-0.43] for RP and 0.30 [95% CI, 0.19-0.47] for EBRT). Adjusted 7.5-year all-cause mortality rates were RP, 17% (95% CI, 11%-23%); EBRT, 18% (95% CI, 14%-24%); and EBRT+BT, 10% (95% CI, 7%-13%). Within the first 7.5 years of follow-up, EBRT+BT was associated with significantly lower all-cause mortality (cause-specific HRs of 0.66 [95% CI, 0.46-0.96] for RP and 0.61 [95% CI, 0.45-0.84] for EBRT). After the first 7.5 years, the corresponding HRs were 1.16 (95% CI, 0.70-1.92) and 0.87 (95% CI, 0.57-1.32). No significant differences in prostate cancer-specific mortality, distant metastasis, or all-cause mortality (≤7.5 and >7.5 years) were found between men treated with EBRT or RP (cause-specific HRs of 0.92 [95% CI, 0.67-1.26], 0.90 [95% CI, 0.70-1.14], 1.07 [95% CI, 0.80-1.44], and 1.34 [95% CI, 0.85-2.11]). Conclusions and Relevance: Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer-specific mortality and longer time to distant metastasis compared with EBRT with androgen deprivation therapy or with RP.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Won Sik Ham; Heather J Chalfin; Zhaoyong Feng; Bruce J Trock; Jonathan I Epstein; Carling Cheung; Elizabeth Humphreys; Alan W Partin; Misop Han Journal: Eur Urol Date: 2016-11-19 Impact factor: 20.096
Authors: Ian S Dayes; Sameer Parpia; Jaclyn Gilbert; Jim A Julian; Ian R Davis; Mark N Levine; Jinka Sathya Journal: Int J Radiat Oncol Biol Phys Date: 2017-05-17 Impact factor: 7.038
Authors: Anusha Kalbasi; Jiaqi Li; Abigail Berman; Samuel Swisher-McClure; Marc Smaldone; Robert G Uzzo; Dylan S Small; Nandita Mitra; Justin E Bekelman Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777
Authors: Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Timothy J Daskivich; Julie Lai; Andrew W Dick; Claude M Setodji; Janet M Hanley; Mark S Litwin; Christopher Saigal Journal: Urology Date: 2016-04-11 Impact factor: 2.649
Authors: Ronald C Chen; Ramsankar Basak; Anne-Marie Meyer; Tzy-Mey Kuo; William R Carpenter; Robert P Agans; James R Broughman; Bryce B Reeve; Matthew E Nielsen; Deborah S Usinger; Kiayni C Spearman; Sarah Walden; Dianne Kaleel; Mary Anderson; Til Stürmer; Paul A Godley Journal: JAMA Date: 2017-03-21 Impact factor: 56.272
Authors: R Bischoff; M Chaloupka; T Westhofen; T Grimm; B Schlenker; P Weinhold; D Tilki; C G Stief; A Kretschmer Journal: Urologe A Date: 2019-05 Impact factor: 0.639
Authors: Kiri A Sandler; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Richard G Stock; Gregory S Merrick; David Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Daniel Y Song; Eric A Klein; Andrew J Stephenson; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen C Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Jonathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King; Amar U Kishan Journal: Eur Urol Date: 2019-04-13 Impact factor: 20.096
Authors: Daniel A Hamstra; Stephanie L Pugh; Herbert Lepor; Seth A Rosenthal; Kenneth J Pienta; Leonard Gomella; Christopher Peters; David Paul D'Souza; Kenneth L Zeitzer; Christopher U Jones; William A Hall; Eric Horwitz; Thomas M Pisansky; Luis Souhami; Alan C Hartford; Michael Dominello; Felix Feng; Howard M Sandler Journal: Radiother Oncol Date: 2019-09-17 Impact factor: 6.280
Authors: Amar U Kishan; Fang-I Chu; Christopher R King; Wendy Seiferheld; Daniel E Spratt; Phuoc Tran; Xiaoyan Wang; Stephanie E Pugh; Kiri A Sandler; Michel Bolla; Philippe Maingon; Theo De Reijke; Nicholas G Nickols; Matthew Rettig; Alexandra Drakaki; Sandy T Liu; Robert E Reiter; Albert J Chang; Felix Y Feng; Dipti Sajed; Paul L Nguyen; Patrick A Kupelian; Michael L Steinberg; Paul C Boutros; David Elashoff; Laurence Collette; Howard M Sandler Journal: Eur Urol Date: 2019-11-10 Impact factor: 20.096
Authors: Alan Pollack; Felix M Chinea; Elizabeth Bossart; Deukwoo Kwon; Matthew C Abramowitz; Charles Lynne; Merce Jorda; Brian Marples; Vivek N Patel; Xiaodong Wu; Isildinha Reis; Matthew T Studenski; Javier Casillas; Radka Stoyanova Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-19 Impact factor: 7.038
Authors: Amar U Kishan; Xiaoyan Wang; Wendy Seiferheld; Laurence Collette; Kiri A Sandler; Howard M Sandler; Michel Bolla; Philippe Maingon; Theo De Reijke; Gerald E Hanks; Nicholas G Nickols; Matthew Rettig; Alexandra Drakaki; Robert E Reiter; Daniel E Spratt; Patrick A Kupelian; Michael L Steinberg; Christopher R King Journal: JAMA Oncol Date: 2019-01-01 Impact factor: 31.777